This phase II trial is evaluating the combination of three immunotherapy drugs (Atezolizumab, Bevacizumab and Cobimetinib) in patients diagnosed with High Grade Serous Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer.
This trial is treating patients with High Grade Serous Ovarian Cancer, Fallopian Tube Cancer Primary Peritoneal Carcinoma.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Targeting the C1 Subtype of High Grade Serous Ovarian Cancer
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
Participants will receive intravenous Bevacizumab (5mg/kg) every two weeks, intravenous Atezolizumab (840mg) every two weeks from Cycle two onwards and Cobimetinib (60mg per day) every day for 21 days.
Recruiting Hospitals Read More